Tianshili: Received drug clinical trial approval notification letter.

Tianshili Announcement: Recently, the wholly-owned subsidiary Jiangsu Diyi received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration for TSL2109 capsules used in advanced solid tumors. TSL2109 capsules are a novel dual-target small molecule inhibitor jointly applied by Jiangsu Diyi and China Pharmaceutical University, with a total investment of 24.6251 million RMB. There are uncertainties in the research and development of new drugs, and the future market competition situation may also change.